Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson has recently revealed encouraging results from trials of nipocalimab, a new drug that could offer hope to adults suffering from generalized myasthenia gravis …
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Rare Autoantibody Diseases Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) recently took a significant stride towards introducing the first treatment for Nonalcoholic Steatohepatitis (NASH) with liver fibrosis. The drug, resmetirom, has cleared a …
Breakthrough in Liver Disease Treatments: Madrigal’s Resmetirom Aims to Be the First Approved NASH Therapy Read More
GLENOLDEN, PA — The Charcot-Marie-Tooth Association (CMTA) has announced a pioneering international research initiative, committing over $500,000 to two multiyear projects aimed at developing treatments for the most prevalent demyelinating …
New Research Initiative Targets Common Forms of Charcot-Marie-Tooth Disease Read More
MALVERN, PA — YPrime, a leading provider of electronic clinical outcomes assessment (eCOA) platforms, has released the results of a comprehensive survey examining the experiences and perspectives of clinical stakeholders …
YPrime Unveils Key Insights into eCOA Adoption and Concerns in Clinical Research Read More
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a Pennsylvania-based biopharmaceutical company, recently announced it has completed enrollment for its Phase 2b/3 study of NRX-101. This patented combination of D-cycloserine, …
NRx Pharmaceuticals Completes Enrollment in Pivotal Trial for Suicidal Bipolar Depression Treatment Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS this week announced a delay in the release of Phase III study data for its promising Parkinson’s Disease drug, buntanetap. The postponement …
Annovis Bio Postpones Release of Phase III Data for Parkinson’s Disease Drug, Buntanetap Read More
MALVERN, PA — In a strategic move that underscores its nearly two-decade legacy of innovation in the clinical trial space, YPrime this week announced a comprehensive brand evolution initiative. The …
YPrime Unveils Bold Brand Evolution, Aiming to Streamline and Accelerate Clinical Trials Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN), a Pennsylvania-based pharmaceutical company, has announced the publication of results from its ReOpen1 and ReOpen2 clinical trials. The findings, published in the reputable Journal …
Optinose’s XHANCE Shows Significant Promise in Chronic Sinusitis Treatment: A Breakthrough Revealed in ReOpen Clinical Trials Read More
BLUE BELL, PA — Mitochon Pharmaceuticals recenlty secured approval from the European Medicines Agency (EMA) to initiate a pioneering Phase I/IIa biomarker study, marking a significant milestone in the fight …
Mitochon Pharmaceuticals Embarks on Groundbreaking Clinical Trial Targeting Four Neurodegenerative Diseases Read More
WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …
Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More